PGT-M for Monogenic Diseases: How It Works and What It Can and Cannot Do

Key Takeaways

PGT-M combines IVF, embryo biopsy, and targeted genetic testing to reduce the chance of transferring an embryo affected by a known single-gene condition. It is most useful when the familial variant is already identified and when patients understand that better embryo selection does not guarantee pregnancy.

PGT-M for Monogenic Diseases

PGT-M, previously often called PGD-M, is used when a couple carries a known single-gene condition and wants to reduce the chance of transferring an affected embryo. It combines IVF, embryo biopsy, and targeted genetic analysis.

It is an important tool, but it should be understood clearly. PGT-M improves embryo selection for a known genetic condition. It does not guarantee pregnancy, eliminate every reproductive risk, or replace good IVF counseling.

Who It Is Used For

PGT-M is usually considered when:

• one or both partners carry a known pathogenic variant
• there is a known risk of transmitting a monogenic disorder
• the familial mutation has already been identified or can be confirmed
• the couple is prepared for IVF and embryo testing as part of treatment

Typical examples include inherited conditions such as cystic fibrosis, thalassemia, sickle cell disease, Huntington disease, or selected cancer-predisposition syndromes, depending on the genetic context.

How the Process Works

The broad steps are:

1. genetic counseling and test design
2. IVF stimulation and egg retrieval
3. fertilization and embryo development
4. embryo biopsy
5. targeted genetic testing
6. selection of embryos not found to carry the targeted condition
7. embryo transfer, usually in a later cycle when needed

The first step is often the most underestimated. The laboratory must confirm exactly which mutation is being tested and validate a reliable assay before embryo analysis can be trusted.

Why Preparation Takes Time

PGT-M is not a same-day add-on. Before embryo testing begins, the genetics team usually needs to:

• confirm the exact familial variant
• review previous genetic reports
• design or validate the testing strategy
• prepare controls and quality checks

This preparation is necessary because the result has to be accurate enough to guide embryo selection.

What PGT-M Can and Cannot Do

PGT-M can reduce the risk of transferring an embryo affected by the targeted monogenic condition. That is its main value.

But it has important limits:

• it does not guarantee implantation
• it does not guarantee live birth
• it does not eliminate all chromosomal or structural risks unless other testing is also specifically planned
• it depends on having embryos available to test
• some cycles may end with no unaffected embryo suitable for transfer

That last point is emotionally difficult for many patients, so expectations should be realistic from the beginning.

Why Counseling Matters

Good PGT-M care is not only laboratory work. It also includes discussing:

• what condition is being targeted
• what result categories are possible
• whether carrier embryos are acceptable for transfer in that scenario
• whether confirmatory prenatal testing will still be recommended
• what happens if no embryo is suitable

These decisions are medical, practical, and sometimes ethical at the same time.

Related Reading

• Can Preimplantation Genetic Testing Be Used for Sex Selection?
• Embryo Grades Like 4AA, 3BB, and 5BC: What They Actually Mean
• IVF Risks and Practical Considerations: What Patients Should Know

FAQ

Is PGT-M the same as standard IVF?

No. It uses IVF as the treatment platform, but adds embryo biopsy and targeted testing for a known inherited condition.

Does PGT-M guarantee a healthy baby?

No. It lowers the chance of transferring an embryo affected by the targeted disorder, but it cannot guarantee pregnancy or eliminate every medical risk.

Can PGT-M be done without knowing the exact mutation?

Usually no. The laboratory generally needs a clearly identified familial variant or a validated strategy before reliable testing can proceed.

Can a cycle end with no transferable embryo?

Yes. That can happen if no embryo develops adequately, if embryos are affected, or if unaffected embryos are not available for transfer.

Is prenatal testing still needed after PGT-M?

Often yes. Many programs still recommend confirmatory prenatal testing because embryo testing, while highly useful, is not considered infallible.

Sources

• American Society for Reproductive Medicine. Indications and management of preimplantation genetic testing for monogenic conditions: a committee opinion (2023).
• ESHRE PGT-M Working Group. ESHRE PGT Consortium good practice recommendations for the detection of monogenic disorders.
• American College of Obstetricians and Gynecologists. Preimplantation Genetic Testing.

Dr. Senai Aksoy

Dr. Senai Aksoy studied and trained in France before returning to Turkey, where he was a founding member of the ICSI team at Sevgi Hospital, Ankara — the country's first ICSI centre (1994-95) — and a co-author on the first Turkish ICSI publications produced in collaboration with the Brussels Van Steirteghem group (Human Reproduction, 1996; PMID 8671323). He helped build the IVF programme at the American Hospital Istanbul and has been running his own fertility practice since 1998.

Verified profiles: PubMed · ORCID · LinkedIn

Read full profile →

The content has been created by Dr. Senai Aksoy and medically approved.